Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.